The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO).
non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.
| INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive lymphoma and is a heterogeneous disease with different histopathologic, phenotypic and genetic features with varying clinical outcomes. 1, 2 Based on gene expression profiling (GEP), the tumor cells are considered to be derived from activated B-cells (ABC) or germinal center B-cells (GCB). 3, 4 Several studies have shown a survival benefit for DLBCL patients with a GCB phenotype compared to an ABC phenotype, 5, 6 whereas other have not. [7] [8] [9] In addition, a third group with unclassified cases (UC) was reported, and proposed to have an inferior outcome similar to ABC-DLBCL. 4, 10 In the updated World Health Organization (WHO) classification of Tumors of Hematopoietic and Lymphoid Tissues, 2 information on the cell-of-origin (COO), either by immunohistochemical (IHC) stainings 6, [11] [12] [13] or by GEP, is required for a definite DLBCL diagnosis.
In clinical practice, however, the use of GEP has not been widely adopted. Most GEP technologies require fresh-frozen tumor tissue.
But in the daily, clinical diagnostic work-up, formalin fixed, paraffinembedded (FFPE) tissue is the primary source, and fresh-frozen material is not routinely collected. Therefore, IHC algorithms have been developed as substitutes and applied with varying concordance to GEP. The most commonly used classification is the Hans algorithm 11 based on the IHC staining results of three proteins: CD10, BCL6 and MUM1, although other systems have also been proposed. 6, 12, 13 However, these IHC algorithms will only identify two groups; GCB or non-GCB, since they cannot identify cases classified as UC by GEP.
In recent years, the NanoString technology Lymph2Cx assay was developed based on GEP, which shows a strong concordance to the original COO model and can be applied on FFPE tissue. 10, [14] [15] [16] This assay uses a limited set of 15 pre-specified genes and five housekeeping genes, and has the potential to identify all three subgroups of DLBCL. 17, 18 In this study, our aim was to investigate the concordance between the Lymph2Cx assay and the IHC algorithm by Hans et al. 11 in relation to clinical characteristics, tumor markers and survival outcome. This was to identify which model would be the best survival predictor in a large cohort of Swedish and Danish DLBCL patients (n = 359).
| METHODS

| Patients
Three hundred and fifty-nine patients were included in the study and Patients with a known previous history of a low-grade lymphoma were excluded. Clinical information was collected from patient records.
Patients were followed-up with clinical examinations and radiologic examinations were used when relapse or progressive disease was suspected. Age-adjusted International Prognostic Index (aaIPI) was used (one point for each: (a) Ann Arbor stage III-IV; (b) elevated serum lactate dehydrogenase (LDH); (c) and ECOG performance status 2-3). Here 0-1 is considered to be low risk and 2-3 is considered to be high risk, in accordance with national guidelines in Sweden and Denmark.
| RNA extraction
Extraction of RNA from FFPE tissue was done according to the AllPrep DNA/RNA Mini Kit for FFPE protocol (Qiagen, Hilden, Germany). That protocol allows for the simultaneous purification of genomic DNA and total RNA from the same biological sample. Purification of RNA was done with the AllPrep column flow-through, using an RNeasy Mini spin column.
| NanoString assay
Samples were analyzed with the Lymph2CX assay on a NanoString instrument according to the manufacture's instructions. The dataset was analyzed using the research use only (RUO) version of the NanoString Lymphoma Subtyping Test (LST), which is based on the Lymph2Cx assay, to determine the COO molecular subtype of each sample. 19 The LST algorithm measures the geometric mean of five housekeeping genes (HK geomean), to ensure RNA quality based on a pre-defined clinical QC threshold of 128. An HK geomean value below 64 was deemed as insufficient RNA quality to provide a subtyping result. A value between 64 and 128 was considered to be borderline quality since it meets previously published thresholds for RNA quality within clinical research studies, 18 were considered to be borderline. Laboratory work was carried out at Uppsala University Hospital according to SOP provided by Nanostring. Data was analyzed by Nanostring (we did not obtain the algorithm).
| Immunohistochemical stainings
The IHC stainings for CD10, BCL2, BCL6, MUM1 and MYC were performed at the different sites according to routine procedures in each diagnostic laboratory. The stainings were re-evaluated semi-quantitatively by each site's hematopathologists (authors MH, MF, MA, SBE, HMP). The
Hans algorithm was applied to classify tumors as GCB or non-GCB by IHC, and included CD10, BCL6 and MUM1 stainings with a cut-off of 30% positive tumor cells. For MYC, a cut-off of 40% was applied and for BCL2 50%. Since insufficient material was a problem in a majority of the cases, FISH analyses for BCL2 and MYC were not performed.
| Cell-of-origin groups
The following subgroups were defined according to GEP or IHC:
1. ABC = ABC type defined by GEP and classified with the Lymph2Cx assay. Additional COO groups were studied and are presented in the supplementary material (Supplementary methods Tables S1 and S2).
GCB-GEP = GCB type defined by GEP and classified with the
| Ethics
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Committees in 
| Statistical analyses
| RESULTS
| Comparison of COO according to the Lymph2Cx assay and the Hans algorithm
Three hundred and fifty-one cases were investigated with IHC markers to determine COO according to the Hans algorithm, where 180 cases (51%) were classified as GCB-IHC, and 171 cases (49%) as non-GCB (Table S3 ). In total, 315 cases were successfully investigated with the NanoString Lymph2Cx assay to determine COO, whereas 44 cases failed to pass the analysis due to insufficient RNA quality. One hundred and sixty-eight cases (53%) were classified as GCB-GEP, 105 cases (33%) as ABC, and 42 cases (13%) as UC according to the Lymph2Cx assay. 
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| Univariate survival analysis
Patients classified as ABC according to the Lymph2Cx assay had significantly inferior five-year survival rates at 58% for OS and 56% for PFS. This is compared with 71% for OS and 69% for PFS in the GCB-GEP group, and 82% for OS and 78% for PFS in the UC-group ( Figure 1A,D) . Patients categorized as non-GCB by the Hans algorithm showed inferior five-year survival rates at 65% for OS and 62% for PFS, compared with 72% for OS and 71% for PFS in the GCB-IHC group (Figure 1B,E) . Patients grouped as ABC according to the Lymph2Cx assay and non-GCB by the Hans algorithm demonstrated inferior five-year survival rates at 53% for OS and 51% for PFS. This is compared with 74% for OS and 72% for PFS in cases that were not ABC and non-GCB combined ( Figure 1C,F ). There were other variables associated with inferior OS ( Table 2 ) and PFS ( 
| UC cases
Of 42 cases categorized as UC according to the Lymph2Cx assay, 33 (79%) were non-GCB and 9 (21%) were GCB-IHC according to the Hans algorithm (Table S3 ). There was a higher proportion of UC with a high expression of MUM1, and a lower proportion with a high expression of CD10, compared with GCB-GEP and ABC cases according to the Lymph2Cx assay (data not shown). Although not statistically significant, tendencies were observed that a higher proportion of UC cases were younger (aged <60 years [P = .09]), and more often presented with B-symptoms (P = .06) compared with GCB-GEP and ABC cases. There were no major differences regarding double expression of MYC and BCL2 (Table S4 ). In supplementary analyses, UC patients showed no statistically significant associations with OS or PFS, in either univariate or in multivariate analysis (Tables S1 and S2 ).
| DISCUSSION
Using GEP to determine the COO of DLBCL is undoubtedly the golden standard, but it requires fresh-frozen material. Thus, it is also of great importance in order to determine the COO with high accuracy on FFPE material, since fresh-frozen material is rarely available in clinical practice. 20 Visco-Young algorithm uses a five-marker model of CD10, GCET1, FOXP1, MUM1, and BCL6. 13 Nevertheless, no IHC algorithm will be 100% concordant with GEP regarding COO, and no IHC algorithm has so far been able to identify the UC cases. Thus, determining COO by GEP is the only way to identify the UC cases.
In our study, the survival outcome for the different GEP groups was well in concordance with previous studies 19, 22, 23 translocations characterized the UC subgroup and were associated with a favorable survival outcome. 37 These findings suggest that further subgrouping of ABC, GCB and UC, by including genetic data might be necessary in order to correctly risk stratify patients with DLBCL.
Our study was performed on a large cohort of DLBCL patients from Sweden and Denmark, where the characterization of COO has been performed both by IHC and GEP on FFPE material. The patient cohort in our study was not truly population-based, but rather based on cases where enough tissue material was available, which may have caused a selection-bias. Furthermore, in DLBCL patients whose tumors are located in deep anatomical sites where surgical biopsy is sparse are not included in most studies, which could add to the question of representativeness. 38 However, clinical characteristics and survival were quite comparable to other studies of DLBCL patients. 8, 25, 39, 40 We did not prepare new slides for the IHC stainings, but instead used the original ones performed by the primary laboratories. Still, the diagnoses and staining results were reevaluated and scored by the participating hematopathologists.
Our cases were classified according to the 2008 WHO classification, and very few were investigated for the presence of MYC, BCL2 and BCL6 rearrangements, which may represent a confounding bias. It was difficult to obtain material for the IHC stainings for MYC and BCL2, only half of the cases were investigated, but this is also observed in large prospective randomized multi-center studies. 8 Obtaining more material for FISH-analyses would have been even more troublesome and would have selected cases with plentiful material. However, this is also the case for similar studies that included patients with HGBCL diagnosed prior to 2016. And, our study is no exception, and our cases have been reported as DLBCL according to the 2008 WHO classification, in order to make our study comparable with other studies. Presumably, some cases of HGBCL with MYC and BCL2 and/or BCL6 rearrangements may be included in our cohort. But, cases with "B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma", according to the 2008 WHO classification, were not included. Many of the "double-hit" lymphomas belong to this category, as does cases with transformation from previous follicular lymphoma, which were also excluded from our study. Thus, "double-hit" lymphomas probably have limited impact on our results. Lastly, the primary aim with our study was to compare the utility of COO classification by the Lymph2Cx assay and IHC, according to the Hans algorithm of de novo DLBCL according to the 2008 WHO classification, not to study the prognostic impact of "double-hit" lymphomas.
In conclusion, GEP combined with IHC to classify cases as ABC/non-GCB is the best predictor of inferior survival, in both uni-and multivariate analyses, probably by identifying cases at the extreme ends of the GCB and ABC spectrum. We also found that cases classified by IHC as non-GCB, were more often GCB-GEP or UC than vice versa for the GCB-IHC cases. Thus, IHC appears to be insufficient to identify cases of the ABC genotype. The Lymph2Cx assay is a robust assay that can be applicable on FFPE material in a clinical setting, in addition to conventional IHC, and is thus possible to implement on a routine clinical basis. Moreover, single as well as double expression of MYC and BCL2 significantly differed between ABC and GCB groups, which affected survival and may thus contribute to the dismal outcome for the ABC group. We propose that both GEP by the Lymph2Cx assay and IHC should be applied to determine COO in order to identify patients with the worst prognosis.
